bioTheranostics Is Now an In-Network Provider with Highmark Health Services for Its CancerTYPE ID® Molecular Test for Metastatic Cancer

FOR IMMEDIATE RELEASE…Aug. 1, 2013…SAN DIEGO… bioTheranostics, a leading provider of molecular diagnostic solutions for cancer, is now an in-network provider with Highmark Health Services, and the company’s CancerTYPE ID® molecular cancer classification test may be eligible for Highmark members based on the member’s individual benefits. Pittsburgh-based Highmark is one of the largest health insurers in the United States and the fourth-largest Blue Cross and Blue Shield-affiliated company, operating health plans that serve 5.3 million members.

CancerTYPE ID, an industry-leading molecular cancer classifier based on the expression of 92 genes, predicts tumor type in patients with metastatic cancers—among the most difficult to diagnose and treat cancers.

Richard Ding, president and CEO of bioTheranostics, said, “We are delighted that Highmark is recognizing the value of the CancerTYPE ID test, which is becoming a standard tool of metastatic cancer management. We have built a strong foundation of evidence supporting CancerTYPE ID—from clinical validity to clinical utility and health outcomes. We are working diligently with the payor community to make this high-value diagnostic test available to patients with metastatic cancer and the clinicians caring for them.”

Ding said that in managing metastatic cancer, achieving diagnostic certainty is critical to optimize site-directed therapies that reduce costs and avoid ineffective therapies for both payors and patients. More than 400,000 patients present with metastatic cancers in the United States each year. An accurate diagnosis is the first step toward personalized medicine, allowing clinicians managing these patients to treat them most effectively using site-specific therapy.

About bioTheranostics

bioTheranostics is the leading solution provider for metastatic cancer management, leveraging its unique expertise in expression profiling to develop a growing array of molecular diagnostic tests for cancer patients. The company operates a CLIA-certified, CAP-accredited diagnostic laboratory to perform its proprietary tests: the CancerTYPE ID® molecular classification test; PRÉCIS® Precision Medicine, which includes biomarker profiles for non-small cell lung and colorectal cancers, and other cancers; and
Breast Cancer IndexSM
, which quantifies risk of recurrence of estrogen receptor-positive, lymph node-negative breast cancer. bioTheranostics, a bioMérieux company, is based in San Diego. For more information, visit www.biotheranostics.com.